

Panacell Biotech begins hunt for long COVID treatment

11 August 2022 | News

To conduct toxicity tests for NK cells, exosomes, and brown adipose-derived stem cells to treat patients with long COVID



According to South Korea-based Panacell Biotech, NK cells, exosomes, and brown adipose-derived stem cells are effective to treat patients with long COVID conditions, or post COVID-19 conditions, as well as those with terminal illness.

Panacell Biotech is specializing in advanced regenerative medical cell therapy using adipose-derived stem cells (ADSC). The company will soon conduct cells' toxicity tests through clinical trials and laboratory animals.

Seung-Ho Choi, CEO of Panacell Biotech, affirmed, "We expect that this clinical trial will reveal therapeutic effects of stem cell therapy."

The Ministry of Food and Drug Safety of South Korea approved Panacell Biotech on April 1 this year as one of the 21 licensed cell treatment facilities.

Currently, in South Korea, there are guidelines for plasma treatment that administers plasma from patients who have recovered from COVID-19 to other patients. Although there already exist COVID-19 treatments, such as Paxlovid, a clear therapeutic effect has not been confirmed yet.

According to the Mayo Clinic, a nonprofit American academic medical center, a whopping one in four people aged 65 or above suffer from aftereffects of COVID-19.

While research on a treatment for COVID-19 is underway around the world, Chinese researchers said they are researching ways to treat COVID-19 patients using stem cells.